Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 404 across all filing types
Latest filing 2024-02-26 Capital/Financing Update
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Form 51-102F3 Material Change Report' and details a material change event involving the closing of a financing offering by Numinus Wellness Inc. It includes specifics about the offering size, price, underwriters, use of proceeds, and insider participation. The form number 51-102F3 is a regulatory filing used in Canadian securities regulation to report material changes. The content focuses on a financing event and is not a full financial report, audit, or earnings release. It is not a report publication announcement since it contains substantive details of the material change itself. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2024-02-26 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed information about a securities distribution, including issuer details, distribution dates, types of securities distributed, purchaser information, compensation paid in connection with the distribution, and related regulatory compliance data. This form is a regulatory filing used to report exempt distributions of securities, typically filed with Canadian securities regulators. It is not an annual report, earnings release, or any other financial report type but a specific regulatory disclosure about securities distribution. The document is comprehensive and contains substantive data about the distribution event, fitting the category of a regulatory filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-02-23 English
News release - English.pdf
Regulatory Filings
2024-02-01 English
News release - English.pdf
Regulatory Filings
2024-01-31 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private placement offering of securities by Revive Therapeutics Ltd. It details the terms of the offering, use of proceeds, and regulatory approvals required. There are no financial statements or detailed financial performance data included. The document is focused on capital raising activity and financing terms, which aligns with a Capital/Financing Update. It is not an annual or interim report, earnings release, or any other report type. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2024-01-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on a research project evaluating Bucillamine for nerve agent exposure. It discusses ongoing research, potential future studies, and regulatory designations but does not contain any financial data, regulatory filings, or detailed financial reports. It is an announcement of a project update rather than a financial report, management discussion, or regulatory filing. The content is typical of a general corporate update or news release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement or corporate update that does not fit other specific categories.
2024-01-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.